Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
An Observational, Multicenter Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
Sponsor: M.D. Anderson Cancer Center
This observational or N/A phase trial investigates Hemophagocytic Lymphohistiocytosis and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Oct 2024 — Present [monthly]
Completed
-
Sep 2024 — Oct 2024 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2022 — Jul 2024 [monthly]
Completed
-
Dec 2021 — Jul 2022 [monthly]
Completed
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Apr 2020 — Nov 2020 [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2019 — Apr 2020 [monthly]
Recruiting
-
Sep 2018 — Sep 2019 [monthly]
Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Swedish Orphan Biovitrum
For direct contact, visit the study record on ClinicalTrials.gov .